New insider activity at Exagen ( (XGN) ) has taken place on March 28, 2025.
Significant shareholder NMSIC Co-Investment Fund, L.P. has offloaded 350,000 shares of Exagen stock, amounting to a total sale value of $1,155,000.
Recent Updates on XGN stock
Exagen Inc. has reported strong financial results for the fourth quarter and full year of 2024, with record total revenue of $55.6 million, driven by improvements in reimbursement and strategic focus on profitability. The company achieved a 300 basis point increase in gross margin and significantly reduced its net loss and adjusted EBITDA loss. Key developments include the launch of new biomarkers for rheumatoid arthritis and lupus, enhancing diagnostic capabilities and promising increased revenue. Despite a decline in testing volume and physician attrition, Exagen’s forward-looking guidance remains positive, projecting revenue growth and aiming for positive adjusted EBITDA by the fourth quarter of 2025. These strategic advancements and financial improvements underscore Exagen’s commitment to innovation and financial stability, making it a promising prospect for investors.
More about Exagen
YTD Price Performance: 37.54%
Average Trading Volume: 151,196
Technical Sentiment Signal: Sell
Current Market Cap: $76.07M